5 completed. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Delayed Graft Function: new trials by email Literature Review of Delayed Graft Function trials Research Report on Delayed Graft Function
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI C1 Esterase Inhibitor, Placebo - End Stage Renal Disease, Kidney Failure | Phase 1 / Phase 2 | Completed | Cedars-Sinai Medical Center | 70 | 2014-09-01 | 2018-06-25 |
| Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) Eculizumab, Placebo - Delayed Graft Function | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 288 | 2014-08-21 | 2018-12-17 |
| Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function OPN-305, Placebo - Delayed Graft Function | Phase 2 | Completed | Opsona Therapeutics Ltd. | 252 | 2012-10-01 | 2017-02-16 |
| I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation I5NP, Saline - Delayed Graft Function, Other Complication of Kidney Transplant | Phase 1 / Phase 2 | Completed | Quark Pharmaceuticals | 374 | 2008-12-01 | 2014-09-18 |
| YSPSL for Prevention of Delayed Graft Function Part B YSPSL, placebo - Kidney Diseases | Phase 1 / Phase 2 | Completed | Y's Therapeutics, Inc. | 60 | 2006-05-01 | 2008-01-29 |
Kidney Diseases (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Kidney Diseases (1)
Sodium Chloride (2) · Complement C1 Inhibitor Protein (1) · Saline Solution (1) · eculizumab (1) · tomaralimab (1)
Alexion Pharmaceuticals, Inc. (1) · Cedars-Sinai Medical Center (1) · Opsona Therapeutics Ltd. (1) · Quark Pharmaceuticals (1) · Y's Therapeutics, Inc. (1)
United States (5) · France (3) · Germany (3) · Spain (3) · Canada (2) · Czechia (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Italy (1) · Netherlands (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Ashley Vo, PharmD (1) · Robert M Miller, FRCS MBBS (1) · Shai Erlich, Ph.D. (1) · Stanley C Jordan, MD (1) · Stefan Hemmerich, PhD (1)